General
Preferred name
OFLOXACIN
Synonyms
LEVOFLOXACIN ()
Ofloxacin (DL8280) ()
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid ()
Hoe-280 ()
DL8280 ()
Tarivid ()
Ocuflox ()
Floxin ()
NSC-727071 ()
Tarivid 400 ()
Ofloxacino ()
Tarivid I.V. ()
Ofloxacine ()
J01MA01 ()
Visiren ()
DL-8280 ()
NSC-758178 ()
HOE 280 ()
Exocin ()
Floxin Otic ()
Ofloxacin-d8 (hydrochloride) ()
P&D ID
PD001409
CAS
82419-36-1
2930288-81-4
Tags
available
drug
Approved by
FDA
First approval
1990
Drug indication
Bacterial infection
hearing loss
Drug Status
investigational
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ofloxacin is a second generation fluoroquinolone antibacterial. (GtoPdb)
ROE Ofloxacin is mainly eliminated by renal excretion, where between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via urine within 48 hours of dosing. About 4-8% of an ofloxacin dose is excreted in the feces and the drug is minimally subject to biliary excretion.
PRICE 29
DESCRIPTION Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).
DESCRIPTION Ofloxacin (Oxaldin) is a fluoroquinolone antibacterial antibiotic. Ofloxacin binds to and inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes involved in DNA replication and repair, resulting in cell death in sensitive bacterial species.
DESCRIPTION Ofloxacin is a broad spectrum fluoroquinolone antibiotic that prevents supercoiling of bacterial chromosomes by DNA gyrase. It is active against Gram-positive and Gram-negative bacteria (Enamine Bioactive Compounds)
DESCRIPTION Fluorinated quinolone antibacterial; interferes with DNA synthesis (LOPAC library)
DESCRIPTION Antibacterial activity against Enterobacter cloacae ATCC 13047; Inhibition of Escherichia coli DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
5
Compound Sets
27
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
External IDs
110
Properties
(calculated by RDKit )
Molecular Weight
361.14
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
4
Aromatic Ring Count
2
cLogP
1.54
TPSA
75.01
Fraction CSP3
0.44
Chiral centers
1.0
Largest ring
6.0
QED
0.87
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
DNA Synthesis
Therapeutic Class
Antibiotics
Pathway
Anti-infection
Target
Topoisomerase
antibiotic
Bacterial
Orthopoxvirus
Source data